At ACM Biolabs we are focused on developing novel vaccines using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using multiple antigens and have a growing pipeline of vaccines.

The company is headquartered in Singapore, and has been operational since 2013.



ACM Biolabs is backed by government bodies, investment companies and strategic corporate investors such as: San Pacific an investment group associated with the Erber Group, an Austrian Animal Healthcare multinational; Nagase, a Japanese multinational with diverse business interests, and; NTUitive, the innovation and enterprise company of the Nanyang Technological University.